Organoids: Unlocking the full potential of precision oncology
What if cancer therapies could be tested on a patient’s own tumor before treatment even begins? Organoids are making this vision increasingly real, offering a powerful bridge between research and personalized care.
)
Organoids in drug research: tiny models, big impact
Organoids are transforming cancer R&D by providing more accurate, patient-relevant models than classical apporaches. And they are becoming a more powerful tool in drug discovery and development.
In the transkript Magazine special edition on organoids, Prof. Dr. Anton Wellstein, CSO at Indivumed, highlights how patient‑derived cellular models help us bringing more precision into the target and drug development process.
By combining patient-derived cellular models with comprehensive molecular profiling, our R&D team can identify tumor‑driving mechanisms, test therapeutic vulnerabilities and anticipate resistance mechanisms early on. “Organoids allow us to recreate the tumor environment in the lab, giving us the insight we need to align therapy development with patient tumor biology,” says Anton Wellstein.
Transformative organoids: accelerating precision oncology
In the same issue, Dr. Parvaneh Mohammadi, Director Primary Cell Modelling at Indivumed, explores the broader impact of “Transformative organoids” on cancer research. She explains how organoids preserve tumor heterogeneity and tissue architecture enabling more meaningful target validation, drug discovery and early clinical insight: “By mimicking tumor tissue, organoids provide more accurate, patient‑relevant models, thereby enhancing patient‑centric target validation, drug discovery and clinical application".
We're pleased to share both full articles as published in transkript Magazine's special edition about organoids, highlighting how organoid technologies are moving from innovation to real‑world impact in cancer drug development.